Q2 Earnings Estimate for Surmodics Issued By Zacks Research

Surmodics, Inc. (NASDAQ:SRDX) – Stock analysts at Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for shares of Surmodics in a note issued to investors on Wednesday, February 19th. Zacks Research analyst D. Dey now forecasts that the company will earn ($0.04) per share for the quarter, up from their previous forecast of ($0.05). The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics’ Q4 2026 earnings at $0.18 EPS, FY2026 earnings at $0.78 EPS and FY2027 earnings at $0.87 EPS.

SRDX has been the topic of a number of other reports. StockNews.com started coverage on shares of Surmodics in a report on Monday, February 3rd. They issued a “hold” rating on the stock. Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a research report on Thursday, January 30th. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $50.00.

Surmodics Price Performance

Shares of SRDX opened at $35.54 on Monday. The firm has a market capitalization of $508.08 million, a PE ratio of -35.19 and a beta of 1.20. The stock’s 50 day moving average is $36.83 and its two-hundred day moving average is $38.26. Surmodics has a twelve month low of $25.17 and a twelve month high of $42.44. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26.

Surmodics (NASDAQ:SRDX) last released its earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Alpine Global Management LLC bought a new stake in shares of Surmodics in the 4th quarter valued at approximately $1,980,000. Squarepoint Ops LLC boosted its holdings in Surmodics by 154.9% during the fourth quarter. Squarepoint Ops LLC now owns 162,066 shares of the company’s stock worth $6,418,000 after buying an additional 98,489 shares during the last quarter. Millennium Management LLC boosted its position in shares of Surmodics by 0.4% during the fourth quarter. Millennium Management LLC now owns 120,344 shares of the company’s stock worth $4,766,000 after purchasing an additional 509 shares in the last quarter. Lighthouse Investment Partners LLC acquired a new position in shares of Surmodics in the 4th quarter valued at approximately $262,000. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Surmodics in the 4th quarter valued at about $11,880,000. Institutional investors and hedge funds own 96.63% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).